Lorcaserin Hydrochloride (Arena)
An FDA advisory panel voted 18 to 4 in favor of the new weight loss drug Lorquess.
FDA Panel Gives Nod to New Diet Drug
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee on Thursday afternoon voted that the benefits of lorcaserin outweigh its risks, despite the modest weight loss provided by the drug and a lack of data to rule out heart valve issues. If approved, lorcaserin would be an option for those with a BMI of 30 or more, or a BMI of 27 with comorbidities related to obesity.
Read more about Lorquess.
Metabolic Medical Centers
Article on Lorquess